All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-12-10T12:24:52.000Z

ASH 2018 | Randomized phase II study comparing 5-day and 10-day decitabine schedule in newly diagnosed acute myeloid leukemia

Dec 10, 2018
Share:

Bookmark this article

Nicolas Short from the MD Anderson Cancer Center, Houston, US, presented data at the 60th American Society of Hematology  Annual Meeting & Exposition, data from a randomized phase II study, which is evaluating the relative safety and efficacy of two different schedules of decitabine, 5-day and 10-day, in older patients with newly diagnosed acute myeloid leukemia (AML).

In this study, 40 patients with newly diagnosed AML were first enrolled and randomized equally to receive decitabine at a daily dose of 20 mg/m2 intravenously for either 5 or 10 consecutive days as induction. An adaptive algorithm was adopted to favor the arm with a higher composite response rate. In total, 71 patients have been enrolled in the 5-day (n = 28; median age = 77 years) and 10-day (n = 43; median age = 78 years) arm.  TP53 mutations were detected in 7/24 patients (29%) in the 5-day arm and in 17/41 patients (41%) in the 10-day arm.

The primary endpoint was the composite response (complete remission [CR] + CR with incomplete platelet count [CRp] + CR with incomplete count recovery [CRi]) rates of the two decitabine schedules. The secondary endpoints included the response duration, overall survival (OS) and the safety of the two schedules.

Key findings:

  • Data below is representative of 5-day and 10-day arms, respectively
    • Composite response: 43% (12/28) vs 40% (17/43), P = 0.78
    • CR rate: 29% (8/28) vs 30% (13/43), P = 0.88
    • Median follow-up = 38.2 months
    • Median duration of CR: 9.4 vs 6.4 months, P = 0.98
    • Median OS: 5.5 vs 6.0 months, P = 0.47
    • Median OS in TP53-mutation positive patients: 5.5 vs 4.9 months, P = 0.55
    • 30-day mortality rates: 4% vs 9%, P = 0.36
    • 60-day mortality rates: 21% vs 25%, P = 0.69
  • There was a trend towards higher TP53 variant allele frequency (VAF) in responders compared to non-responders, P = 0.07
  • Responding patients had a significant decline in TP53VAF at the end of cycle 1, P < 0.001
  • Two patients with undetectable TP53 had the longest CR duration

The composite response rate between the 5-day and 10-day arms were very similar with a difference of 3%. As a result, the trial was terminated early due to “futility.” However, the findings of this study demonstrate that in older patients with newly diagnosed AML, decitabine given for either 5 or 10 consecutive days resulted in similar response rates, early mortality, and survival.  There were no differences in response or survival were observed in any subgroup, including TP53-mutated AML.

Nicolas Short concluded by stating that decitabine given for 5 consecutive days and 10 consecutive days are “reasonable non-intensive backbone for combination, investigational regimens.”

  1. Short N. et al. Five-day versus ten-day schedules of decitabine in older patients with newly diagnosed acute myeloid leukemia: Results of a randomized phase II study. 2018 Dec 1; Oral Abstract #8460th ASH Annual Meeting and Exposition, San Diego, CA.

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 5 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox